A Phase 3 interventional study of tadalafil and tadalafil in Hypertension, Pulmonary, sponsored by Eli Lilly and Company. Completed at 10 sites in 10 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2013-04-09.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing tadalafil in Hypertension, Pulmonary — 3 open to participants now, 3 under way, 2 of them phase 3. Tadalafil · Hypertension, Pulmonary.
Among the 18 studies testing tadalafil in Hypertension, Pulmonary, this one is the 3rd largest by enrollment, is one of 2 that started in 2005, is one of 8 in phase 3, and was the 2nd registered.
1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.
Browse Hypertension, Pulmonary studies →3 of the 18 studies testing tadalafil in Hypertension, Pulmonary are open now, in 12 countries. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 35–89
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–85
Actelion · Sites in Belarus, Belgium, Bulgaria and 10 more countries
Ages 2+
By country, each count listing its studies:
Tadalafil: first FDA approval 2003 (CIALIS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 163 Hypertension, Pulmonary studies recruiting now, 99 (61%) set no upper age limit and 26 (16%) stop at 75 or younger; 39 take children under 18; 24 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 9 · Phase 4 5
First in 2005; this study’s year is marked. 2 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 357 is above the median of 35 across 649 interventional studies indexed under Hypertension, Pulmonary.
Median enrollment 40 across the 18 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 18 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 3 studies filed under Hypertension, Pulmonary — fewer than ten, so there is no comparison to draw.
2 of the studies testing tadalafil in Hypertension, Pulmonary that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05179876Phase 3ActelionA Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option | 2027-01-31 |
| NCT05844462Phase 3Assistance Publique - Hôpitaux de ParisTadalafil for Severe Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease | 2027-10 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing tadalafil in Hypertension, Pulmonary, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study to determine the long term safety of tadalafil in patients with increased blood pressure in the blood vessel that carries blood from the right heart to the lungs and to see if it will keep the disease from getting worse.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
20 milligram (mg) tadalafil taken once a day
Drug: tadalafil
40 mg tadalafil tablet taken once a day
Drug: tadalafil
20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
Also known as: LY450190, Cialis, IC351
40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
Also known as: LY450190, Cialis, IC351
Number of Participants With Adverse Events (AEs)
A summary of serious and all other non-serious AEs, which include adverse events reported for laboratory tests and vital signs, is located in the Reported Adverse Event module.
Time frame: Baseline (Double-Blind Period) up to Week 243 (End of Open-Label Period)
6-Minute Walk Distance (6MWD) at Baseline and Weeks 16, 28, 40 and 52
6MWD measured the distance a participant was able to walk unassisted in 6 minutes.
Time frame: Baseline and Weeks 16, 28, 40 and 52
Borg Dyspnea Assessment at Baseline and Weeks 16, 28, 40 and 52
Borg dyspnea score is a participant rated measure of their greatest degree of shortness of breath during exertion (6-minute walk test). Score ranged from 0 (nothing at all) to 10 (very, very severe \[maximal\]).
Time frame: Baseline and Weeks 16, 28, 40 and 52
Probability of No Pulmonary Arterial Hypertension (PAH) Deterioration at Weeks 16, 28, 40 and up to 52
World Health Organization Functional Classification Assessment (WHO FC) is a method of classifying disease severity in PAH. The classes are: Class I: pulmonary hypertension (PH) but without resulting limitation of physical activity, Class II: PH resulting in slight limitation of physical activity, Class III: PH resulting in marked limitation of physical activity, Class IV: PH with inability to carry out any physical activity without symptoms. Deterioration of WHO FC is defined as moving to a higher WHO FC within one visit. Results are presented as Kaplan-Meier estimates (% probability) of remaining free from WHO FC deterioration after a given time.
Time frame: Baseline and Weeks 16, 28, 40 and 52
| Milestone | Tadalafil 20 mg Double Blind | Tadalafil 40 mg Double-Blind | Tadalafil 40 mg Open-Label |
|---|---|---|---|
| Started | 63 | 294 | 0 |
| Received at least one dose of study drug | 63 | 294 | 0 |
| Completed | 52 | 241 | 0 |
| Not completed | 11 | 53 | 0 |
| Withdrew: Death | 2 | 9 | 0 |
| Withdrew: Adverse event | 3 | 16 | 0 |
| Withdrew: Withdrawal by subject | 3 | 8 | 0 |
| Withdrew: Investigator decision | 1 | 5 | 0 |
| Withdrew: Sponsor decision | 0 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 |
| Withdrew: New drug pulmonary atrial hypertension | 1 | 10 | 0 |
| Withdrew: New condition or starts new therapy | 0 | 2 | 0 |
| Milestone | Tadalafil 20 mg Double Blind | Tadalafil 40 mg Double-Blind | Tadalafil 40 mg Open-Label |
|---|---|---|---|
| Started | 0 | 0 | 286 |
| Completed | 0 | 0 | 217 |
| Not completed | 0 | 0 | 69 |
| Withdrew: Adverse event | 0 | 0 | 11 |
| Withdrew: Death | 0 | 0 | 40 |
| Withdrew: Investigator decision | 0 | 0 | 5 |
| Withdrew: Lost to follow-up | 0 | 0 | 2 |
| Withdrew: Other | 0 | 0 | 3 |
| Withdrew: New drug pulmonary atrial hypertension | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 6 |
A summary of serious and all other non-serious AEs, which include adverse events reported for laboratory tests and vital signs, is located in the Reported Adverse Event module.
| participants | Tadalafil 20 mg or 40 mg Double-Blind and 40 mg Open-Label |
|---|---|
| Serious AEs | 184 |
| Other Non-Serious AEs | 334 |
6MWD measured the distance a participant was able to walk unassisted in 6 minutes.
| meters (m) | Tadalafil 20 Milligrams (mg) Double-Blind | Tadalafil 40 mg Double-Blind |
|---|---|---|
| Distance walked at Baseline (n=63, 287 | 397.74 ± 71.74 | 375.38 ± 93.41 |
| Distance walked at Week 16 (n=58, 272) | 396.37 ± 77.01 | 381.47 ± 96.86 |
| Distance walked at Week 28 (n=55, 250) | 406.41 ± 106.76 | 384.97 ± 95.03 |
| Distance walked at Week 40 (n=51, 241) | 411.81 ± 78.72 | 386.57 ± 94.04 |
| Distance walked at Week 52 (n=51, 235) | 415.31 ± 79.82 | 394.00 ± 91.56 |
| Endpoint-Week 52 or LOCF (n=60,281) | 401.52 ± 90.29 | 379.80 ± 99.12 |
Borg dyspnea score is a participant rated measure of their greatest degree of shortness of breath during exertion (6-minute walk test). Score ranged from 0 (nothing at all) to 10 (very, very severe \[maximal\]).
| units on a scale | Tadalalfil 20 Milligrams (mg) | Tadalafil 40 mg |
|---|---|---|
| Score at Baseline (n=62, 287) | 3.41 ± 2.38 | 3.65 ± 2.43 |
| Score at Week 16 (n=58, 271) | 3.41 ± 2.48 | 3.51 ± 2.35 |
| Score at Week 28 (n=54,249) | 3.46 ± 2.40 | 3.44 ± 2.21 |
| Score at Week 40 (n=51, 240) | 3.21 ± 2.43 | 3.38 ± 2.27 |
| Score at Week 52 (n=51,235) | 3.68 ± 2.43 | 3.29 ± 2.16 |
| Endpoint-Week 52 or LOCF (n=60,281) | 3.75 ± 2.34 | 3.54 ± 2.36 |
World Health Organization Functional Classification Assessment (WHO FC) is a method of classifying disease severity in PAH. The classes are: Class I: pulmonary hypertension (PH) but without resulting limitation of physical activity, Class II: PH resulting in slight limitation of physical activity, Class III: PH resulting in marked limitation of physical activity, Class IV: PH with inability to carry out any physical activity without symptoms. Deterioration of WHO FC is defined as moving to a higher WHO FC within one visit. Results are presented as Kaplan-Meier estimates (% probability) of remaining free from WHO FC deterioration after a given time.
| probability (%) no PAH deterioration | Tadalafil 20 Milligrams (mg) Double-Blind | Tadalafil 40 mg Double-Blind |
|---|---|---|
| Week 16 (n=57, 262) | 95 (85 to 98) | 96 (93 to 98) |
| Week 28 (n=50, 238) | 88 (77 to 94) | 90 (86 to 93) |
| Week 40 (n=45, 222) | 81 (68 to 89) | 88 (83 to 91) |
| Week 52 (n=33,136) | 81 (68 to 89) | 85 (80 to 89) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tadalafil 20 mg or 40 mg Double-Blind and 40 mg Open-Label | — | 184/357 (51.5%) | 334/357 (93.6%) |
| Event | Tadalafil 20 mg or 40 mg Double-Blind and 40 mg Open-Label |
|---|---|
| Right ventricular failureCardiac disorders | 28/357 |
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 26/357 |
| PneumoniaInfections and infestations | 16/357 |
| Cardiac failure congestiveCardiac disorders | 10/357 |
| SyncopeNervous system disorders | 10/357 |
| Cardiac failureCardiac disorders | 9/357 |
| Gastrointestinal haemorrhageGastrointestinal disorders | 8/357 |
| AnaemiaBlood and lymphatic system disorders | 7/357 |
| Atrial fibrillationCardiac disorders | 7/357 |
| Chest painGeneral disorders | 7/357 |
| Event | Tadalafil 20 mg or 40 mg Double-Blind and 40 mg Open-Label |
|---|---|
| HeadacheNervous system disorders | 107/357 |
| DiarrhoeaGastrointestinal disorders | 77/357 |
| NasopharyngitisInfections and infestations | 64/357 |
| Back painMusculoskeletal and connective tissue disorders | 64/357 |
| Oedema peripheralGeneral disorders | 63/357 |
| Upper respiratory tract infectionInfections and infestations | 63/357 |
| DizzinessNervous system disorders | 61/357 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 55/357 |
| CoughRespiratory, thoracic and mediastinal disorders | 54/357 |
| PalpitationsCardiac disorders | 52/357 |
| Age Continuous(years) | Tadalafil 20 Milligrams (mg) Double-Blind | Tadalafil 40 mg Double-Blind | Total |
|---|---|---|---|
| Mean | 53.04 ± 15.58 | 53.94 ± 15.36 | 53.78 ± 15.38 |
| Sex: Female, Male(Participants) | Tadalafil 20 Milligrams (mg) Double-Blind | Tadalafil 40 mg Double-Blind | Total |
|---|---|---|---|
| Female | 48 | 230 | 278 |
| Male | 15 | 64 | 79 |
| Region of Enrollment(participants) | Tadalafil 20 Milligrams (mg) Double-Blind | Tadalafil 40 mg Double-Blind | Total |
|---|---|---|---|
| Belgium | 2 | 5 | 7 |
| Canada | 4 | 38 | 42 |
| France | 3 | 22 | 25 |
| Germany | 6 | 34 | 40 |
| Ireland | 0 | 1 | 1 |
| Italy | 4 | 25 | 29 |
| Japan | 5 | 17 | 22 |
| Spain | 2 | 4 | 6 |
| United States | 33 | 139 | 172 |
| United Kingdom | 4 | 9 | 13 |
| Race(participants) | Tadalafil 20 Milligrams (mg) Double-Blind | Tadalafil 40 mg Double-Blind | Total |
|---|---|---|---|
| White | 48 | 243 | 291 |
| Asian | 7 | 22 | 29 |
| Black or African American | 5 | 23 | 28 |
| American Indian or Alaska Native | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 2 | 2 |
| American Indian or Alaska Native/White | 0 | 1 | 1 |
| Black or African American/Native Hawaiian or Other | 1 | 0 | 1 |
| Weight(kilograms (kg)) | Tadalafil 20 Milligrams (mg) Double-Blind | Tadalafil 40 mg Double-Blind | Total |
|---|---|---|---|
| Mean | 73.92 ± 18.90 | 75.26 ± 19.80 | 75.02 ± 19.63 |
| Ethnicity(participants) | Tadalafil 20 Milligrams (mg) Double-Blind | Tadalafil 40 mg Double-Blind | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 36 | 40 |
| Not Hispanic or Latino | 59 | 258 | 317 |
| Etiology(participants) | Tadalafil 20 Milligrams (mg) Double-Blind | Tadalafil 40 mg Double-Blind | Total |
|---|---|---|---|
| Idiopathic | 37 | 186 | 223 |
| Related to Collagen Vascular Disease | 16 | 62 | 78 |
| Associated with Atrial Septal Defect | 3 | 26 | 29 |
| Related to Anorexigen Use | 4 | 11 | 15 |
| Surgical Repair, of at least 1 Year Duration | 3 | 9 | 12 |
| Current Bosentan Use(participants) | Tadalafil 20 Milligrams (mg) Double-Blind | Tadalafil 40 mg Double-Blind | Total |
|---|---|---|---|
| Yes | 37 | 155 | 192 |
| No | 26 | 139 | 165 |
The record gives a start of Dec 2005, a primary completion of Feb 2012 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tadalafil